The BECN1 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the BECN1 gene in the 143B human osteosarcoma cell line. This polyclonal knockout model provides a genetically mixed loss-of-function system for studying BECN1-dependent autophagy. The pool of edited cells is designed for robust functional assays without requiring clonal isolation.
The 143B host cell line is a highly metastatic human osteosarcoma model with a TP53 mutation, isolated from a malignant osteoblastic bone tumor. 143B cells are characterized by aggressive proliferation, invasive behavior, and chemoresistance. The TP53-mutant background predisposes these cells to genomic instability, making them a pertinent model for investigating tumor progression and metastasis in the context of autophagy deficiency.
BECN1 (Beclin-1) is a core component of the autophagy-initiating PI3K class III complex, where it interacts with VPS34, VPS15, and ATG14 to nucleate autophagosome formation. BECN1 activity is positively regulated by AMPK and ULK1 phosphorylation, while Bcl-2 binding inhibits its function. Downstream targets include LC3-I to LC3-II conversion and p62/SQSTM1 degradation. BECN1 also interacts with UVRAG, Rubicon, AMBRA1, and TRAF6, integrating signals from mTORC1, AMPK, and DAPK to coordinate autophagy with apoptosis and endocytic trafficking.
BECN1 knockout in 143B cells disrupts autophagy, impairing clearance of damaged organelles and aggregates. This defect is expected to amplify TP53-related genomic instability, promoting a more aggressive tumor phenotype. Given BECN1??s role as a tumor suppressor and its loss in various cancers, this model is valuable for studying how autophagy deficiency drives osteosarcoma metastasis, chemoresistance, and recurrence. It enables exploration of cross-talk between autophagy, PI3K/AKT/mTOR signaling, and apoptotic pathways.
Research applications include autophagy deficiency studies, chemoresistance mechanisms, and drug screening for autophagy modulators. Representative assays include Western blotting for BECN1, LC3, and p62; LC3 autophagic flux assays with bafilomycin A1; immunofluorescence for LC3 puncta; and cell proliferation, migration, and invasion assays. Chemosensitivity testing can reveal the role of autophagy in drug resistance. For further details, please contact Ascent Research.
